<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="130376">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01404741</url>
  </required_header>
  <id_info>
    <org_study_id>VidazaAlloStudy</org_study_id>
    <nct_id>NCT01404741</nct_id>
  </id_info>
  <brief_title>5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS)</brief_title>
  <official_title>Comparison Between 5-azacytidine Treatment and 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      5-azacytidine treatment prolongs survival in patients with myelodysplastic syndrome (MDS),
      but does not cure the disease. Allogeneic stem cell transplantation is a curative treatment
      option but is associated with a high risk treatment-related morbidity and mortality. In the
      current trial allogeneic stem cell transplantation will be compared to 5-azacytidine only
      treatment according to donor availability in elderly patients with MDS (55-70 years).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      5-azacytidine treatment prolongs survival in patients with myelodysplastic syndrome (MDS),
      but does not cure the disease. Allogeneic stem cell transplantation is a curative treatment
      option but is associated with a high risk treatment-related morbidity and mortality.
      Dose-reduced conditioning prior transplantation allows also treatment of elderly patients
      with MDS. In the current trial allogeneic stem cell transplantation will be compared to
      5-azacytidine only treatment according to donor availability in elderly patients with MDS
      (55-70 years).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>three years</time_frame>
    <description>compare to overall survival of patients who receive after 4 cycles of 5-azacytidine either allogeneic stem cell transplantation or continuous 5-azacytidine if no compatible donor is available overall 230 patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>response</measure>
    <time_frame>three years</time_frame>
    <description>Comparison of response according to International Working Group Response Criteria between both arms:
- Examinations of bone marrow (count of blasts) and peripheral blood (hematological improvement)after schedule of study assessments (after cycle 4 in both arms, after cycle 8 and after months 12-24-36 in the 5-azacytidine treatment and on day 100, day 180, months 12-24-36 after allogeneic stem cell transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event-free survival</measure>
    <time_frame>three years</time_frame>
    <description>comparison of event free survival in both arms (230 pat.):
- evaluation of survival status (relapse, date of relapse, alive or death) in the whole study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>three years</time_frame>
    <description>Comparison of overall survival between both arms (230 pat.).
- evaluation of survival status (alive or death/date of death) in the whole study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>impact of Comorbidity-index on outcome</measure>
    <time_frame>three years</time_frame>
    <description>impact of comorbidity-index on outcome after study entry and prior to allogeneic stem cell transplantation (according definitions and weighted scores of comorbidities by Sorror et al):
physical examination
laboratory values(creatinine,Alt, AST, bilirubin, etc.)
apparative diagnostics (echo,lufu,ECG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related mortality</measure>
    <time_frame>three years</time_frame>
    <description>compare treatment related mortality in both arms (230 pat.):
- death according to treatment in both arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of toxicity</measure>
    <time_frame>three years</time_frame>
    <description>the evaluation of toxicity will be performed according to the reporting guidelines as per NCI CTCAE in the whole study period:
adverse events grade 3 and 4
cytopenia grade 3 and 4 only be reported as AE which are judged by the investigator as clinically relevant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>three years</time_frame>
    <description>Comparison of quality of life between both arms with the quality of life core questionnaire QLQ-C30 and the treatment specific high-dose chemotherapy module QLQ HD-C29 to assess the quality of life of cancer patient. The questionnaire has to be answered after the fourth cycle, 6 months, 1 year, 2 years and 3 years after both treatment arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>5-azacytidine treatment until progress</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5-azacytidine until progress</description>
  </arm_group>
  <arm_group>
    <arm_group_label>allogeneic stem cell transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>after 4 cycles 5-azacytidine and if donor available: allogeneic stem cell transplantation after reduced intensity conditioning</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic stem cell transplantation</intervention_name>
    <description>donor available, after 4 cycles 5-azacytidine allogeneic stem cell transplantation after reduced conditioning</description>
    <arm_group_label>allogeneic stem cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>5-azacytidine until progress</intervention_name>
    <description>if no donor available 5-azacytidine until progress or toxicities</description>
    <arm_group_label>5-azacytidine treatment until progress</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with proven de novo or therapy-related MDS / CMML (WBC &lt;13 GPT/l)according
             to FAB and risk profile according to IPSS: intermediate II- risk or high-risk or
             intermediate I with high-risk cytogenetic (according to IPSS, taking into account
             that IPSS, however, was not validated for t- MDS), patients with secondary AML
             (according to WHO) and blasts ≤ 30 % (= RAEB-t according to FAB)

          -  Previously untreated or maximal 1 cycle of 5-azacytidine (Vidaza®)

          -  Male or Female; Age 55 - 70 years

          -  Understand and voluntarily sign an informed consent form

          -  ECOG performance status of ≤ 2 at study entry

          -  Adequate renal and liver function: creatinine and bilirubin &lt; 3 x the upper limit of
             normal

          -  Sufficient cardiac function (ejection fraction &gt; 30 %)

        Exclusion Criteria:

          -  Blasts &gt; 30 % in bone marrow at time of diagnosis

          -  Central nervous involvement

          -  Severe irreversible renal, hepatic, pulmonary or cardiac disease, such as

          -  Total bilirubin, SGPT or SGOT ≥ 3 times upper the normal level

          -  Left ventricular ejection fraction &lt; 30 %

          -  Creatinine clearance &lt; 30 ml/min

          -  DLCO &lt; 35 % and/or receiving supplementary continuous oxygen

          -  Pregnant or breastfeeding female subject

          -  Patients with a life-expectancy of less than six months because of another
             debilitating disease

          -  Serious psychiatric or psychological disorders

          -  Uncontrolled invasive fungal infection at time of registration

          -  Known positive for HIV or acute infectious hepatitis, type A, B or C

          -  Participation in another study with ongoing use of unlicensed investigational product
             from 28 days before study enrollment until the end of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolaus Kroeger, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Centre Hamburg-Eppendorf, Stem-Cell-Transplantation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolaus Kroeger, Prof.</last_name>
    <phone>+49-40-7410-55864</phone>
    <email>nkroeger@uke.uni-hamburg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marion Heinzelmann</last_name>
    <phone>+49-40-7410-54188</phone>
    <email>mheinzel@uke.uni-hamburg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lutz Uharek, Prof. Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Lutz Uharek, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie v. Lilienfeld-Toal, PD Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Marie v.Lilienfeld-Toal, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uwe Platzbecker, PD Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Uwe Platzbecker, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guido Kobbe, PD Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Guido Kobbe, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dietrich W. Beelen, Prof. Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Dietrich W. Beelen, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard Noppeney, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Richard Noppeney, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Wolfgang Goethe-Universität</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gesine Bug, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Gesine Bug, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Göttingen</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gerald Wulf, Prof. Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Gerald Wulf, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolaus Kroeger, Prof.</last_name>
      <phone>+49-40-7410-55864</phone>
      <email>nkroeger@uke.uni-hamburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Marion Heinzelmann</last_name>
      <phone>+49-40-7410-54188</phone>
      <email>mheinzel@uke.uni-hamburg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Nicolaus Kroeger, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Stadler, Dr.Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Michael Stadler, Dr.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universität zu Köln</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christof Scheid, PD Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Christof Scheid, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan A. Klein, PD Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Stefan A. Klein, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helge Menzel, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Helge Menzel, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthias Stelljes, PD Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Matthias Stelljes, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg</name>
      <address>
        <city>Nürnberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kerstin Schäfer-Eckart, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Kerstin Schäfer-Eckart, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitätsklinik II</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wolfgang Bethge, PD Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Wolfgang Betghe, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard F. Schlenk, PD Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Richard F. Schlenk, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 20, 2016</lastchanged_date>
  <firstreceived_date>June 30, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MDS</keyword>
  <keyword>CMML</keyword>
  <keyword>allogeneic stem cell transplantation</keyword>
  <keyword>5-azacytidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
